Fundraising Fox
🦊/People
Sign in

Amy Kruse

Investor

General Partner at Prime Movers Lab · Chief Investment Officer, Satori Neuro at Satori Capital · Board director at Gilgamesh Pharma · Board director at Motif Neurotech · Board director at Morphoceuticals

Washington DC-Baltimore Area

Writes $2M – $30M checks

Find your path to Amy

113 people in our graph share verified history with Amy — schools, employers, funds. One of them is your warm intro.

Mike HickeyunlockedAmy: together at Prime Movers Lab (2021–2022)
Amy: together at Satori Capital
×2Amy: together at Gilgamesh Pharma
×7Amy: together at Prime Movers Lab

About

Amy Kruse—PhD neuroscientist who led DARPA neuroscience and human-performance programs—guides neurotech (BCI, sensing) startups from board seats through scientific and regulatory complexity to enhance human performance.

Invests in

BiotechDeep TechEnergyHardwareMobility & TransportationSpace Tech

Board director at Gilgamesh Pharma

Intro paths

→

In turn, Amy can intro founders to Gilgamesh Pharma's investors below.

Gilgamesh Pharma's investors · 1

Prime Movers LabJackson · $2M – $30M checks · since 2026

Co-founders at Gilgamesh Pharma

AKAndrew Kruegel
Andrew KruegelExecutive Officer, Director
JSJonathan Sporn
Jonathan SpornExecutive Officer, Director

Board director at Motif Neurotech

Intro paths

→

In turn, Amy can intro founders to Motif Neurotech's investors below.

Motif Neurotech's investors · 10

Arboretum VenturesAnn Arbor · $5M – $15M checks · since 2024Capital FactoryAustin · since 2024Divergent CapitalNew York · $250K – $1M checks · since 2024Dolby Family VenturesSan Francisco · since 2024KdT VenturesAustin · $500K – $3M checks · since 2024Prime Movers LabJackson · $2M – $30M checks · since 2024PsyMed VenturesBerkeley · since 2024re.Mind CapitalLondon · since 2024TMC Venture FundHouston · since 2024XEIA Venture PartnersSan Francisco · since 2024

Co-founders at Motif Neurotech

SSSameer Sheth
Sameer ShethFounder
SSSunil Sheth
Sunil ShethFounder

Board director at Morphoceuticals

Intro paths

→

In turn, Amy can intro founders to Morphoceuticals's investors below.

Morphoceuticals's investors · 1

Prime Movers LabJackson · $2M – $30M checks · since 2023

Experience

  1. Satori CapitalGeneral Partner & Chief Investment Officer - Satori Neurocurrent2023 — present
  2. Prime Movers LabVenture Partnercurrent2022 — present
  3. Prime Movers LabGeneral Partner2021 — 2022
  4. Prime Movers LabPartner & Principal Biologist2020 — 2021
  5. Gilgamesh PharmaceuticalsBoard Membercurrent2021 — present
  6. Paradromics Inc.Board Membercurrent2021 — present
  7. CognixionBoard Membercurrent2021 — present

Skills & more

Mental HealthStrategic Planning

From Amy's professional profile.

Deals · 6

Gilgamesh PharmaBoard seat

via Prime Movers Lab · filed Mar 2026 · $15M raise

CognixionBoard seat

via Prime Movers Lab · filed Jan 2025 · $6M raise

Motif NeurotechBoard seat

via Prime Movers Lab · filed Jan 2024 · $21.6M raise

MorphoceuticalsBoard seat

via Prime Movers Lab · filed Jan 2023 · $9.8M raise

Dodo OmniDataBoard seat

via Prime Movers Lab · filed Nov 2021 · $6M raise

Gilgamesh PharmaceuticalsBoard seat

via Prime Movers Lab · filed May 2021 · $34.7M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Sources: SEC Form D filings · curated public sources.

Colleagues at Prime Movers Lab

Aaron Mandell
Venture Partner at Prime Movers Lab
Andre Jabban
Partner and Head of Capital Formation at Prime Movers Lab
Andrei Iancu
Venture Partner at Prime Movers Lab
Bill Gross
Venture Partner at Prime Movers Lab
Blake Scholl
Venture Partner at Prime Movers Lab
Brandon Simmons
General Partner at Prime Movers Lab
Brantley Sydnor
Operations Manager at Prime Movers Lab
Carly Anderson
Investor at Prime Movers Lab

Network9

Blake MycoskieScout
Angel
Bradley HorowitzScout
Investor at Wisdom Ventures
Dakin SlossScout
Founder & General Partner at Prime Movers Lab
Esther DysonScout
Founder of Wellville; chairman of EDventure Holdings
Stephen HaysScout
Investor at What If Ventures
David Beazley
Managing Partner at Alumni Ventures
Duncan Turner
General Partner at SOSV
John Kuelper
Senior Managing Director at Ascension Ventures
Wesley Yiu
Principal at Alumni Ventures

Investors connected to Amy in public investor directories — a warm-intro map.

Frequently asked questions

Who is Amy Kruse?
Amy Kruse—PhD neuroscientist who led DARPA neuroscience and human-performance programs—guides neurotech (BCI, sensing) startups from board seats through scientific and regulatory complexity to enhance human performance.
Where does Amy Kruse work?
Amy Kruse is General Partner at Prime Movers Lab and Board director at Gilgamesh Pharma and Board director at Motif Neurotech and Board director at Morphoceuticals.
What does Amy Kruse invest in?
Amy Kruse invests in Biotech, Deep Tech, Energy, Hardware, Mobility & Transportation, Space Tech.
What check size does Amy Kruse write?
Amy Kruse typically writes checks of $2M – $30M.
What boards does Amy Kruse sit on?
Amy Kruse holds tracked board seats at Cognixion, Dodo OmniData, Gilgamesh Pharma, Gilgamesh Pharmaceuticals, Morphoceuticals, Motif Neurotech, Paradromics Turning Data Into Medicine.
What companies has Amy Kruse invested in?
Investments tracked here include Beckley Psytech, Cognixion, Dimension Inx, Feel Therapeutics, Gilgamesh Pharmaceuticals, Iridia, Morphoceuticals, Motif Neurotech, NextSense, Paradromics, TARA Mind.
Where did Amy Kruse go to school?
Amy Kruse studied at University of Illinois Urbana-Champaign (Ph.D., Neuroscience); University of Illinois Urbana-Champaign (B.S., Cell and Structural Biology).

Same school

Shared employers